Se­vere ad­verse events mar the end of Roche’s PhI­II for ‘break­through’ he­mo­phil­ia drug

With Phase III da­ta loom­ing for its close­ly-watched he­mo­phil­ia drug ACE910 (emi­cizum­ab), Roche says that in­ves­ti­ga­tors have tracked four se­ri­ous cas­es of blood clot­ting among pa­tients tak­ing the ther­a­py. And the news im­me­di­ate­ly buoyed shares of both Shire and No­vo Nordisk, which are first in line for see­ing their fran­chis­es take a hit from the ex­per­i­men­tal ther­a­py.

Roche says that there were two cas­es of throm­boem­bol­ic events and two cas­es of throm­bot­ic mi­croan­giopa­thy among pa­tients with break­through bleed­ing who were be­ing treat­ed with Shire’s FEI­BA and No­vo’s Novo­Sev­en, by­pass­ing agents that car­ry a throm­bo­sis warn­ing, ac­cord­ing to Reuters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER